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Abstract
Background: Artesunate-amodiaquine (AS-AQ) was introduced in Ghana as the first line drug for treatment of 
uncomplicated malaria in 2004. We report the perceptions of malaria and malaria treatment behaviour, the community 
awareness of and perceptions about AS-AQ two years after the introduction of this ACT treatment for malaria.
Methods: Two surveys were conducted; a cross-sectional survey of 729 randomly selected household heads (urban-
362, rural-367) and 282 women with children < 5 years (urban-121, rural-161) was conducted in 2006. A district wide 
survey was conducted in 2007 to assess awareness of AS-AQ. These were complemented with twenty-eight focus 
group discussions (FGDs) and 16 key informant interviews (KII) among community members and major stakeholders in 
the health care delivery services. All nine (9) health facilities and five (5) purposively selected drug stores were audited 
in order to identify commonly used anti-malarials in the study area at the time of the survey.
Results: Majority of respondents ( > 75%) in the sampled survey mentioned mosquito bites as the cause of malaria. 
Other causes mentioned include environmental factors (e.g. dirty surroundings) and standing in the sun. Close to 60% 
of the household heads and 40% of the care-givers interviewed did not know about AS-AQ. The community 
respondents who knew about and had ever taken AS-AQ perceived it to be a good drug; although they mentioned 
they had experienced some side effects including headaches and body weakness. Co-blistered AS-AQ was available in 
all the government health facilities in the study area. Different formulations of ACTs were however found in urban 
chemical shops but not in rural chemical stores where monotherapy antimalarials were predominant.
Conclusion: The knowledge of fever as a symptom of malaria is high among the study population. The awareness of 
AS-AQ therapy and its side-effect was low in the study area. Community education and sensitization, targeting all 
categories of the population, has to be intensified to ensure an efficient implementation process.
Background
It has been estimated that about 3000 malaria deaths
occur among African children each day [1], with about
0.5 billion clinical malaria cases and 2-3 million severe
malaria episodes occurring annually [2]. The children
who do not die from the severe form of malaria may suf-
fer brain damage or experience cognitive and learning
deficits [3]. The World Bank ranked malaria as a leading
cause of most disability-adjusted life years in Africa with
an estimated 35 million future life-years lost from disabil-
ity and premature deaths [4]. The loss of growth in coun-
tries with endemic malaria is estimated at about 12 billion
US Dollars annually [5]. This has contributed to the cycle
of poverty in sub-Saharan Africa [6].
Poor perceptions about malaria and poor malaria drug
treatment practices have contributed to widespread resis-
tance of Plasmodium falciparum malaria to commonly
used monotherapy such as chloroquine and sulfadoxine-
pyrimethamine leading to challenges in the control of
malaria [7]. Artemisinin-based combination therapy
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(ACT) has been demonstrated to remarkably improve
treatment efficacy [8] and are currently recommended by
the World Health Organization to overcome the problem
of drug resistance and for effective control of malaria [9].
Current efforts to eliminate malaria greatly depend on
the perceptions of anti-malarial interventions. The per-
ceptions of malaria and community treatment seeking
behaviour have been widely investigated in relation to
monotherapies, mainly chloroquine and sulphadoxine-
pyrimethamine in Ghana and other African countries.
Understanding the perceptions of malaria, treatment
behaviour, awareness of and prompt access to the new
and effective ACT drugs are deemed important steps to
malaria control and elimination.
In Ghana, public education on causes, prevention, and
actions for treatment of malaria has been ongoing for
several years. Such educational campaigns are even more
crucial now to maintain the effectiveness of ACTs. In
2004, Ghana changed its firstline malaria treatment pol-
icy from chloroquine to the use of artesunate-amodi-
aquine (AS-AQ) combination. The policy change process
involved active education campaign through media
advertisements, community durbars and workshops
among health-workers.
We conducted two surveys in the Kintampo North and
South Districts of Ghana; the first was between March.
2006 and July 2006 and a repeat in June 2007 in order to
determine the perceptions of malaria and malaria treat-
ment behaviours. We also assessed the awareness of and
perceptions about AS-AQ in the communities two years
after it was introduced as the first line drug for treatment
of malaria.
Methods
Study site
The study was carried out in the Kintampo North and
South Districts of Ghana. These two districts cover in
total, an area of 7162 km2 with a resident population of
approximately 130,000. The study area is located within
the forest-savannah transitional ecological zone in central
Ghana where community members are predominantly
subsistent farmers. Plasmodium falciparum malaria pre-
dominates in this area. Community surveys showed the
prevalence of malaria parasitemia to be about 50% among
children less than 10 years of age (symptomatic/asymp-
tomatic) and malaria transmission is perennial, with
entomological inoculation rate of 269 infective bites per
person per year [10]. Mean monthly temperatures range
between 18°C to 38°C and rainfall averages 1250 mm per
annum, making conditions optimal for vector abundance.
Plasmodium falciparum resistance to chloroquine was
greater than 40.0%, similar to that recorded in other parts
of the country [11]. Seven (7) clinics and two (2) hospitals
are located in the two districts. Malaria microscopy is
available for malaria diagnosis in the hospitals. Malaria
Rapid Diagnostic Test (RDT) kits are supposed to be used
in peripheral clinics. Malaria diagnosis at the chemical
shops is mainly presumptive. Antimalarials for uncompli-
cated malaria are registered to be sold over the counter in
the study area and other parts of Ghana.
Quantitative survey
Two surveys were conducted; the first survey was
between March 2006 and July 2006 among seven hundred
and twenty-nine (729) randomly selected households
within the study area, using the urban/rural strata. The
household database of the Kintampo Health and Demo-
graphic Surveillance Systems (KHDSS) was used as a
sampling frame. A maximum of three persons made up of
the household head, a woman with a child less than five
years and a household member who had taken AS-AQ
prior to the survey were interviewed in each household.
Trained field workers interviewed respondents about
their perceptions of malaria, malaria treatment behav-
iours, and the awareness of AS-AQ therapy as first line
antimalarial using structured questionnaires. Malaria
treatment behaviours were assessed with reference to the
last episode of malaria experienced by the respondent in
the last two months. Respondents were made to identify
the types/brands of antimalarials displayed from a collec-
tion of antimalarials available in the study area; these
included AS-AQ brands that they were supposed to be
aware of or had taken prior to this survey.
The second survey was a district-wide household sur-
vey conducted from January to June 2007 involving the
entire households in the Kintampo Health and Demo-
graphic Surveillance System (KHDSS) in order to further
assess the awareness of AS-AQ. Respondents to ques-
tions during this survey were household heads or their
representatives. The KHDSS is a system that conducts six
(6)-monthly censuses in the entire population of Kin-
tampo North and South districts in the central part of
Ghana. It generates data from the entire population that
informs public health policy in Ghana. In both surveys,
awareness of AS-AQ was defined as ability to mention
the name of AS-AQ or identify AS-AQ as a replacement
of chloroquine for the treatment of malaria.
Qualitative methods
Twenty-eight focus group discussions (FGDs) were con-
ducted among community members. The FGDs assessed
local names for the syndrome of signs and symptoms that
describe malaria and its treatment practices. Responses
were used to develop the quantitative survey tools. FGD
participants from rural and urban areas of the study were
randomly selected using a list from KHDSS database of
community resident members. In each area, selected par-
ticipants were categorised based on sex, age groups, andAsante et al. BMC Public Health 2010, 10:409
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w o m e n  wi t h  c h i l d r e n  l e s s  t h a n  fi v e  y ea r s  o f  a g e .  Ea c h
FGD session involving between 8 to 12 participants was
moderated by a study team member as well as recorded
for transcription and analysis.
Nineteen (19) key informant interviews (KII) were also
conducted among stakeholders in healthcare delivery
including; a District Director of Health Services, nine (9)
primary doctor/medical assistants located at all the nine
(9) health facilities in the study area. Additionally, four (4)
traditional healers and five (5) out of seventeen (17) drug
store operators were selected in the study area based on
their accessibility and availability to community members
in the study area. By the fifth interview with a drug store
operator, there were no new emerging themes being
obtained as determined by continuous analysis of already
conducted interviews. Drug stores have similar charac-
teristics such as personnel who manage them and their
scope of work. The shops are managed by community
members without qualified pharmacist. They are the low-
est level of pharmaceutical care providers who are
allowed to supply only over-the-counter medicines by
retail. The shops are licensed and regulated by the Ghana
Pharmacy Council which ensures their adherence to
standards of community based pharmaceutical care
throughout Ghana including the study area. The inter-
views explored their knowledge of and perceptions about
the anti-malaria policy change and methods used in iden-
tifying and reporting the side-effects of AS-AQ.
Health facility survey
A survey of all nine (9) health facilities and five (5) purpo-
sively selected drug stores were carried out to identify
commonly used anti-malarial drugs in the study area.
The selection was based on their accessibility and avail-
ability to community members in the study area. Samples
of these anti-malarial drugs were displayed during the
group discussions and surveys.
Data entry, cleaning and analyses
Qualitative data from FGDs and IDIs were recorded
using a recorder, transcribed verbatim, checked for com-
pleteness and accuracy. Answers to qualitative questions
were grouped and categorised using QRS NVIVO version
7 qualitative software. Responses were analysed to iden-
tify themes that addressed the study's objectives and
emerging themes. Quotes that best described the various
themes were included to support quantitative findings.
Quantitative data was checked for completeness and con-
sistency and all queries resolved after double data entry.
Clean data were analysed using Stata 9.0 (TX, U.S.A).
Demographic data such as educational status and sex
were summarised into percentages; ages were put into
age-groups and summarised as percentages.
Ethical issues
Ethical approval to conduct the study was granted by the
Ghana Health Service Ethics Review Committee and the
Kintampo Health Research Centre Ethics Committee.
Community entry involved explaining the study to key
community opinion leaders followed by community dur-
bars/meetings. At these meetings, the study's aims, objec-
tives, risk and benefits were explained to all participants
and a signed/thumb printed written consent was
obtained from each respondent and participants of the
FGDs. All data collected were kept in locked cabinets to
ensure confidentiality.
Results
There were 729 household heads, 81 household members
and 282 care-givers who were respondents for the quanti-
tative survey (Table 1). All care-giver respondents in rural
and urban areas were females; majority of them had had
no education; this was relatively higher in the rural areas
compared with the urban areas. Respondents in the focus
group discussions had similar social characteristics as
respondents in the quantitative survey as they were
invited from the same communities.
Perception of Malaria and Its Causes
Malaria was identified as the most disturbing disease
affecting both children and adults in the study area. The
local terms associated with malaria varied based on eth-
nic diversity; among the majority of Akan speaking com-
munities, the main terms used were "ebunu", "etiridii" and
"ahobene". Others described malaria as ntontom yadie i.e.
mosquito disease. The majority of respondents men-
tioned mosquito bites as one of the factors leading to
malaria disease (Table 2). A high proportion of respon-
dents mentioned standing or walking in the sun (range
21.1-47.1%) or eating contaminated food (range 23.1-
34.2%) as factors leading to malaria. Dirty environments
and weedy surroundings were mentioned less frequently
by all respondents (Table 2).
Community knowledge about the signs and symptoms of 
malaria
A comprehensive list of signs and symptoms of malaria
was provided by the study population (Table 3). Respon-
dents in all the FGDs conducted mentioned hot body
(especially at night), headache, restlessness, loss of appe-
tite, bitterness in the mouth, body weakness, body and
joint pains, dizziness, tired feeling, cold, chills and a feel-
ing that makes you fond of sitting in the sun as signs and
symptoms associated with malaria Yellow eyes; dark or
ye l low  urine ,  a nd ye ll ow vom i t us  we r e  associa t ed wit h
severity of malaria.
"Your whole body will become hot, your mouth 
becomes bitter and you don't have the appetite for any-Asante et al. BMC Public Health 2010, 10:409
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thing" (FGD Atta Akura, female 35-49). "You will feel 
cold, weak, with bitterness in the mouth and when you 
urinate, the urine is very yellowish in colour" (FGD 
Sunkwa, mothers less than 30 years).
Most of the care-givers of children less than five years
of age associated malaria with hot body (Urban -82.6%
(95% CI 74.7 - 88.9); Rural -81.4% (95% CI 74.4. - 87.1)
temperature when interviewed whiles adults associated
body weakness with malaria (Table 3).
Health seeking behavior among community members
Self-medication was found to be a common practice for
managing most disease conditions in the study popula-
tion. Community members mentioned that management
of malaria is initially at home and then a follow-up to the
hospital if the situation of the patient did not improve. In
critical situations, community members who initially
seek traditional treatment resort to treatment at the
health facility. These findings were apparent from com-
ments made in the focus group discussions:
"What happens is, you have to use some local herbs 
and see but when it becomes severe then you go to the 
hospital." (FGD mothers less than 30 years, Kokuma)
"Most often, we usually manage the sickness at home a 
little. We are able to manage it by giving for instance 
paracetamol syrup. If we see that after some days the 
situation is not improving then we take the child to the 
hospital" (IDI mother above 30 years)
Participants who use orthodox medicines usually resort
to the use of analgesics, antipyretics and antimalarials
which they usually obtain from drug vendors/peddlers or
licensed chemical shops as the first treatment option. Left
over drugs previously used to treat similar conditions
were also used for treating a patient with another onset of
malaria. Participants also use home-made herbal prepa-
rations from different plant parts. In some cases, herbal
preparations peddled by traditional healers or sold in
shops are used. These preparations are boiled and drunk,
inhaled or bathed. The potency of some of these prepara-
tions is determined by how frequent one urinates. If one
urinates a lot after taking these herbs, it is believed that
the treatment is good and that the sickness is being
passed out through the urine.
"I also know of "dua gene" the Ashantis call it "gyedua", 
you add "nsempuadua" leaves and cassava leaves. You 
boil them together, and then drink some and bath 
some. You will realize that the 'fever' will go. If I drink 
it, I will urinate all the 'fever' away" (FGD Jema East 
males 50 years and above)
There was the perception among respondents that tra-
ditional treatment worked better for them whilst others
be l i ev ed  i n  o rt h od o x  t r e a t m e n t.  I n  bo t h  i n s t a n c e s,  t h e
Table 1: Characteristics of respondents in 2006 household survey
Household Heads Household members Care-giver
Urban Rural Urban Rural Urban Rural
N = 362 N = 367 N = 38 N = 43 N = 121 N = 161
Sex (%)
% Female 45.0 29.2 76.3 72.1 100.0 100.0
Age groups (%)
14 - 18 0.8 0.0 13.2 0.0 0.0 0.0
19 - 24 3.6 0.5 13.2 4.6 18.2 22.4
25 - 34 16.6 13.4 15.7 25.6 45.5 41.0
35 - 49 40.1 40.3 34.2 44.2 32.2 35.4
50 - 59 16.5 25.4 13.2 16.3 4.1 1.2
60 + 22.4 20.4 10.5 9.3 0.0 0.0
Educational characteristics (%)
None 43.9 54.0 21.1 41.9 43.8 50.9
Primary 9.1 13.9 18.4 14.0 19.8 16.2
Middle School, JHS 32.9 26.7 47.3 39.5 28.9 32.3
Technical/Commercial/SHS 9.1 4.1 5.3 2.3 6.6 0.6
Post Sec./college/training 3.9 1.3 7.9 2.3 0.0 0.0
University 1.1 0.0 0.0 0.0 0.9 0.0A
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Table 2: Factors spontaneously mentioned by respondents as the cause(s) of malaria from 2006 survey*.
Household Head Household Member Care-giver
Urban Rural Urban Rural Urban Rural
N = 361 N = 365 N = 38 N = 43 N = 121 N = 161
%, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI)
Mosquito bites 74.8 (270, 70.0 - 79.2) 78.9 (288, 74.4 - 83.0) 89.5 (34, 75.2 - 97.1) 76.7 (33, 61.4 - 88.2) 84.3 (102, 76.6 - 90.3) 76.4 (123, 69.1 - 82.7)
Weedy Surroundings/Stagnant water 32.1 (116, 27.3 - 37.2) 39.2 (34.1 - 44.3) 36.8 (14, 21.8 - 54.0) 32.6 (14, 19.0 - 48.5) 24.8 (30, 17.4 - 33.5) 24.2 (39, 17.8 - 31.6)
Dirty Surroundings 38.0 (137, 32.9 - 43.2) 46.3 (169, 41.0 - 51.6) 34.2 (13, 19.6 - 51.4) 55.8 (24,39.9 -70.9) 40.5 (49, 31.7 - 49.8) 32.3 (52, 25.2 - 40.1)
Eating contaminated food 23.3 (84, 19.0 - 28.0) 29.3 (107, 24.7 - 34.3) 23.7 (9, 11.4 - 40.2) 25.6 (11, 13.5 - 41.2) 23.1 (28, 16.0 - 31.7) 34.2 (55, 26.9 - 42.0)
Standing/walking in the sun 41.0 (148, 35.9 - 46.2) 47.1 (172, 41.9 - 52.4) 21.1 (8, 9.6 - 37.3) 34.9 (15, 21.0 - 50.9) 33.1 (40, 24.8 - 42.2) 36.0 (28.6 - 43.9)
Sweet foods 2.2 (8, 0.9 - 4.3) 3.6 (13, 1.9 - 6.0) 2.6 (1, 0.1 - 13.8) 7.0 (3, 1.5 - 19.1) 2.5 (3, 0.5 - 7.1) 1.2 (2, 0.2 - 4.4)
*multiple answers were allowed.A
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Table 3: Knowledge of signs and symptoms of malaria among respondents from 2006 survey.
Household head Household member Caregiver
Urban Rural Urban Rural Urban Rural
N = 361 N = 365 N = 38 N = 43 N = 121 N = 161
Symptom %, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI)
Bodily Weakness 59.0 (213, 53.7 - 64.1) 62.5 (228, 57.3 - 67.5) 68.4 (26, 51.3 - 82.5) 62.8 (27, 46.7 - 77.0) 34.7 (42, 26.3 - 43.9) 31.1 (50, 24.0 - 38.8)
Hot body 46.8 (169, 41.6 - 52.1) 36.4 (133, 31.5 - 41.6) 50.0 (19, 33.3 - 66.6) 37.2 (16, 23.0 - 53.3) 82.6 (100, 74.7 - 88.9) 81.4 (131, 74.5 - 87.1)
Loss of appetite 44.3 (160, 39.1 - 49.6) 33.2 (121, 28.3 - 38.2) 50.0 (19, 33.3 - 66.6) 39.5 (17, 25.0 - 55.6) 30.6 (37, 22.5 - 39.6) 29.8 (48, 22.9 - 37.5)
Chills 40.4 (146, 35.3 - 45.7) 45.2 (165, 40.0 - 50.5) 44.7 (17, 28.6 - 61.7) 37.2 (16, 23.0 - 53.3) 21.5 (26, 14.5 - 29.9) 24.2 (39, 17.8 - 31.6)
Headache 37.1 (134, 32.1 - 42.3) 29.9 (109, 25.2 - 34.8) 36.8 (14, 21.8 - 54.0) 32.6 (14, 19.1 - 48.5) 15.7 (19, 9.7 - 23.4) 13.7 (22, 8.8 - 19.9)
Vomiting 19.7 (71, 15.7 - 24.1) 16.4 (60, 12.8 - 20.6) 15.8 (6, 6.0 - 31.2) 16.3 (7, 6.8 - 30.7) 42.2 (51, 33.2 - 51.4) 41.0 (66, 33.3 - 49.0)
Dizziness 18.8 (68, 14.9 - 23.2) 28.8 (105, 24.2 - 33.7) 13.2 (5, 4.4 - 28.1) 30.2 (13, 17.2 - 46.1) 6.6 (8, 2.9 - 12.6) 9.3 (15, 5.3 - 28.9)
Diarrhea 7.2 (26, 4.7 - 10.4) 8.5 (31, 5.8 - 11.8) 10.5 (4, 2.9 - 24.8) 9.3 (4, 2.6 - 22.1) 12.4 (15, 7.1 - 19.6) 21.7 (35, 15.6 - 28.9)
Cough 1.7 (6, 0.6 - 3.6) 1.5 (6, 0.6 - 3.5) 0.0 (0, -) 7.0 (3, 1.5 - 19.1) 3.3 (4, 0.9 - 8.2) 3.7 (6, 1.4 - 7.9)A
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Table 4: First point of call when the respondents are sick from 2006 survey.
Household heads Household members Care-givers
Urban Rural Urban Rural Urban Rural
N = 275 N = 280 N = 33 N = 32 N = 95 N = 135
%, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI) %, (n, 95% CI)
Chemical Shop 51.6 (142, 45.6 - 57.7) 41.8 (117, 35.9 - 47.8) 30.3 (10, 15.6 - 48.7) 40.6 (13, 23.7 - 59.4) 44.2 (42, 34.0 - 54.8) 36.3, (49, 28.2 - 45.0)
Hospital 18.2 (50, 13.8 - 23.3) 15.4 (43, 11.3 - 20.1) 24.2 (8, 11.0 - 42.2) 25.0 (8, 11.4 - 43.4) 21.1 (20, 13.3 - 30.6) 17.0 (23, 11.1 - 24.5)
Use of traditional medicine 10.9 (30, 7.4 - 15.2) 23.2 (65, 18.3 - 28.6) 9.1 (3, 1.9 - 24.3) 9.4 (3, 2.0 - 25.0) 1.0 (1, 0.0 - 5.7) 9.6 (13, 5.2 - 16.0)
Health Centre 8.0 (22, 5.1 - 11.9) 7.1 (20, 4.4 - 10.8) 24.2 (8, 11.1 - 42.2) 12.5 (4, 3.5 - 29.0) 13.7 (13, 7.5 - 22.3) 12.6 (17, 7.5 - 19.4)
Private Clinic 2.9 (8, 1.3 - 5.6) 4.3 (12, 2.2 - 7.4) 3.1 (1, 0.1 - 15.7) 0.0 (0, -) 9.5 (9, 4.4 - 17.2) 2.2 (3, 0.5 - 6.3)
Use of left over orthodox 
medicine at home
2.9 (8, 1.3 - 5.6) 4.3 (12, 2.2 - 7.4) 9.1 (3, 1.9 - 24.3) 3.1 (1, 0.1 - 16.2) 9.5 (9, 4.4 - 17.2) 10.4 (14, 5.8 - 16.8)
Drugs from Friend/relative 2.6 (7, 1.0 - 5.2) 0.4 (1, 0.0 - 1.9) 0.0 (0, -) 0.0 (0, -) 1.0 (1, 0.0 - 5.7) 3.0 (4, 0.8 - 7.4)
Herbalist 0.7 (2, 0.1 - 2.6) 0.7 (2, 0.1 - 2.5) 0.0 (0 - ) 0.0 (0, -) 0.0 (0, -) 0.7 (1, 0.0 - 4.0)
Other 2.2 (6, 0.8 - 4.7) 2.9 (8, 1.2 - 5.5) 0.0 (0 - ) 9.4 (3, 2.0 - 25) 0.0 (0, -) 8.2 (11, 4.1 - 14.1)
Total 100 100.0 100.0 100 100.0 100.0Asante et al. BMC Public Health 2010, 10:409
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effect of treatment was associated with one's body includ-
ing their 'blood' (a description referable to the hematolog-
ical system) and its compatibility with whichever drug
taken.
"For me if I get malaria, I can go to the hospital ten 
times but it would not go, unless I use herbs before it 
will go."(FGD Mo line females 25-34 years)
"If the child's body is hot, go for mango or pawpaw 
leaves and boil it and give it to the child. So when you 
do that his body will cool down." (FGD 19-24 females, 
Kandige)
C h e m i c a l  s h o p s  w e r e  f o u n d  t o  b e  a  c o m m o n  p l a c e
where respondents first go for advice on what drugs to
buy after describing their sick conditions to the chemical
seller. In the rural areas where drug peddlers are well
patronized, drugs including antimalarials, analgesics, and
antibiotics are sold. These health seeking practices were
supported in the quantitative survey (Table 4).
The community's health seeking practices were further
affirmed by a health worker in an IDI; she was of the view
that community members initially report at chemical
shops for drugs when they get sick and only report at the
health facility when the illness gets complicated.
Respondents attached importance in seeking health
care at the health facility; lack of money for such services
was however considered a major barrier for early treat-
ment at the health facility as demonstrated in the state-
ment;
"Normally we need the hospital drugs, but sometimes 
when the sickness comes, the money you need to go to 
the hospital becomes difficult to get so you go for the 
leaves" (FGD Atta Akura female 35-49 years).
Awareness of AS-AQ among sampled households and all 
households in the study area
Awareness of AS-AQ was generally low among the sam-
pled population in both rural and urban areas (Table 5).
Among household heads, urban awareness was 33.2%
(95% CI 28.2 - 38.3) compared with the rural folks 32.6%
(95% CI 27.9 - 37.8); caregivers in the urban parts had
awareness levels of 39.5% (95% CI 30.9 - 48.9) compared
with rural folks, 46.5% (95% CI 38.7 - 54.6). Awareness of
AS-AQ was much lower in both urban and rural areas
when the district-wide survey was conducted among all
households or their representatives in the study area. The
urban awareness was 25.8% (95% CI 24.6 - 27.0) com-
pared to rural -6.9% (95% CI 6.4 - 7.5).
Community members who were aware of AS-AQ
reported of diverse sources of their information about
AS-AQ, the commonest being the local radio and/or the
National Television stations. About sixty seven percent
(66.7%, 95% CI 57.5 - 75.0) of household heads in the
urban areas and 48.7% (95% CI 39.4 - 58.1) of household
heads in the rural areas reported the radio and television
as the main sources of information; similar responses
were solicited from care-givers where information among
the urban population was 52.6% (95% CI 35.8 - 69.0)
compared with the rural folks 34.8% (95% CI 21.0 - 50.9).
Other sources of information about AS-AQ among care-
givers included health talk sessions during child welfare
clinics, health talk at churches, and discussions with rela-
tives or in chemical shops owners. In rural areas,17.6%
(95% CI 11.3 - 25.7) of household heads and 37.2% (95%
CI 23.0 - 53.3) care-givers had heard of AS-AQ during
community durbars organised by health workers.
Suggestions on ways to promote awareness of AS-AQ
were assessed in community FGDs. Participants in the
Table 5: Proportion of respondents who were aware of AS-AQ among sampled population in 2006 and district wide survey 
in 2007
Sampled population in 2006 N % 95% CI
Household head
Urban (N = 361) 120 33.2 28.2 - 38.3
Rural (N = 365) 119 32.6 27.9 - 37.8
Care giver
Urban (N = 121) 48 39.6 30.9 - 48.9
Rural (N = 160) 74 46.3 38.7 - 54.6
District wide population 2007
Urban (N = 5339) 1378 25.8 24.6 - 27.0
Rural (N = 9787) 683 6.9 6.4 - 7.5Asante et al. BMC Public Health 2010, 10:409
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discussions who were hearing about AS-AQ for the first
time were ready to learn about it and tell others. Radio
discussions, community durbars and church announce-
ments were methods suggested to be used in disseminat-
ing information about AS-AQ. It was however observed
that community member had difficulty pronouncing AS-
AQ.
Respondents who had been treated with AS-AQ them-
selves or care-givers whose children had previously been
treated with AS-AQ perceived AS-AQ to be a good drug.
This is because they had observed that it took a long time
for them or their children to have another malaria attack
following an initial treatment. They attributed this per-
ception to the effectiveness of the drug. The need to
make AS-AQ available at the community level for treat-
ment of malaria was emphasised during the FGDs. These
themes are illustrated below.
"The drug is good because ever since I used the drug on 
the child he hasn't experienced fever again, it is three 
months now." (A Female participant aged 25-34 years 
in a rural area)
"Because of hardship, some people are not able to go to 
the hospital. I think if we get some in our community 
drug store it will help a lot" (A male participant aged 
between 19-24 years in a rural area)
Awareness of artesunate-amodiaquine (AS-AQ) among 
health workers and drug sellers
Government sector
Heads and staff of all government health facilities includ-
ing district hospitals, health centres and community clin-
ics were aware of AS-AQ and were already prescribing
the drug to their clients. It was observed that, each of the
clinics in the study area had a treatment chart which was
said to be very helpful in determining the dosage for cli-
ents based on their ages and weights.
Formal Private sector
Private clinics headed by nurses or doctors and chemical
sellers were well informed about the policy change from
chloroquine to AS-AQ. They were also aware of the ratio-
nale for this policy change and had practical experiences
of increasing treatment failure with the continual use of
chloroquine. Their information about AS-AQ was
through periodic updates by the Pharmacy Council of
Ghana and the district health directorates.
Traditional sector
Traditional healers were aware of AS-AQ but did not
know about the details of the dosage and their side-effect
profile. They had however heard that patients who took
AS-AQ had headaches. Traditional healers referred
patients who complained about any side-effect after tak-
ing AS-AQ back to the government health facilities
where the drug was obtained. They were willing to refer
illnesses that they could not deal with to the clinic for fur-
ther management.
"Some of my patients bring some (AS-AQ) from the 
hospital.... What I can say about the drug is that when 
it came on board some people were complaining of 
headache and so on but since then I haven't head any-
thing about it again... I don't prescribe AS-AQ but if I 
realize that the person's illness is above me, then I 
direct the person to hospital". (A Traditional healer in 
an urban area)
Both private and public health workers applauded the
change in anti-malarial policy from the use of chloro-
quine to AS-AQ; their main worry was about the
reported side-effects: body weakness and headache
which they attributed to amodiaquine. Some health
workers admitted to administering lower doses of amodi-
aquine in order to minimise side-effects. Additionally,
they advised their clients to eat adequately before taking
AS-AQ to prevent general weakness which was thought
to be the commonest side-effect.
Motivational factors to use AS-AQ
The motivation to use of AS-AQ by household heads and
members (N = 807) were assessed in the survey. The per-
ceived efficacy of AS-AQ was the highest (82.7%, 95% CI
79.9 - 85.2) motivating factor for its use, whilst affordabil-
ity was lowest (54.3%, 95% CI 50.8 - 57.8) (Figure 1).
Availability and Use of AS-AQ and other antimalarials
The commonest anti-malarial drugs observed in rural
chemical shops were chloroquine (CQ); kinaquine 4-4-2
(KQ)  which is brand of chloroquine; Sulfadoxine-
Pyrimethamine (SP) in brands such as Malafan or Fan-
sider; and amodiaquine (AQ). Chemical sellers identified '
high cost' as a barrier to stocking AS-AQ since their cli-
ents found it expensive to buy. They mentioned chloro-
quine, Malafan and Kinaquine 4-4-2 as the antimalarials
commonly sold within the last three months. The cost of
treatment dosage of these drugs varied significantly; USD
$0.10 for CQ and USD $0.60 for SP. The cost of brands of
artesunate alone found in urban chemical shops ranged
between USD 3.00 and USD 3.50
Chloroquine/Kinaquine were found to be the common-
est antimalarial drugs used by household heads (urban =
50.9% (95% CI 44.8 - 57.0), rural = 50.4% (95% CI 44.3 -
56.4) and care-givers (urban = 67.4% (95% CI 57.0 - 76.6),
rural = 53.3% (95% CI 44.6 - 62.0 ) (Figures 2 and 3).
The use of AS-AQ was comparatively uncommon in
both urban and rural areas; 12.4% (95% CI 8.7 - 16.8) of
household heads in the urban and 13.6% (95% CI 9.8 -
18.1) in the rural; for care-givers 10.5% (95% CI 5.2 - 18.5)
of the urban and 8.1% (95% CI 4.1 - 14.1) of the rural folks
had used the AS-AQ available in health facilities. The use
of other brands of AS-AQ combination such as Amotex,Asante et al. BMC Public Health 2010, 10:409
http://www.biomedcentral.com/1471-2458/10/409
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Figure 1 Factors that motivate household heads and members (N = 807) to use artesunate -amodiaquine in 2006 survey.
Figure 2 Drugs used by household heads in urban (N = 275) and rural areas (N = 280) for treating their last episode of malaria in 2006 sur-
vey.
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
50.0
55.0
60.0
SP  CHQ/ KQ AQ/ CQ AS alone AS/ AQ  Amotex A -plus Camsunate Herbs
P
e
r
c
e
n
t
a
g
e
 
(
%
)
Brand of antimalarial
Urban
RuralAsante et al. BMC Public Health 2010, 10:409
http://www.biomedcentral.com/1471-2458/10/409
Page 11 of 14
A-plus  and Camsunate were uncommon (< 7.0% in all
cases). However among these uncommonly used brands,
A-plus  was frequently used among the respondents
(household head: urban = 5.5% (95% CI 3.1 - 8.8), rural =
6.1% (95% CI 3.6 - 9.5); care-givers: urban = 2.1% (95% CI
0.2 - 7.4), rural = 0.7% (95% CI 0.0 - 4.1) ).
The use of herbal treatment was most popular in the
rural areas as 34.2% (95% CI 28.6 - 40.1) of the urban
household heads still use herbs for malaria treatment
compared with 52.5% (95% CI 45.8 - 57.8) of rural house-
hold heads; for care-givers, 13.7% (95% CI 7.5 - 22.3) of
urban compared to 31.9% (95% CI 24.1 - 40.4) of the rural
folks still use herbs.
Challenges in delivering artesunate-amodiaquine (AS-AQ)
AS-AQ is administered on the bases of age and weight
and requires the use of birth date records and weighing
scales. Poor quality weighing scales were identified by
health workers as a challenge at the health facilities in the
districts. Another challenge faced by health workers is
the act of breaking tablets into smaller bits to get the right
proportions for varying weights and ages.
"In fact, all the health facilities have weighing scales 
only that they are not durable. They are bathroom 
scales. We keep buying and buying. We need the solar 
type which is so expensive and only available at some 
UNICEF programmes" (A health worker in charge of a 
health policy implementation)
"The problem was the problem of divisibility. As I said 
earlier on, when I came back from the training, I was a 
little bit confused on the division aspect of the dosage 
but now the availability of the chart am okay with 
that. (A health worker in charge of a health facility)"
Side-effect Surveillance records
Both government and private health facilities and drug
shops that stocked AS-AQ did not keep any records on
known or reported side-effects.
Discussion
In the 1990's several studies in Ghana and other African
countries demonstrated poor knowledge about the causa-
tion of malaria leading to gross socio-cultural influence in
household malaria treatment behaviour [12,13]. For
Figure 3 Drugs used by care-givers in urban (N = 95) and rural (N = 135) areas for treating their children's last malaria episode in 2006 sur-
vey.
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instance in Ghana, malaria transmission was associated
with various misconceptions. Mosquito bites were associ-
ated with skin rashes whilst the nuisance made from
hammering of the mosquito with sleep disturbances;
hardly was the mosquito associated with malaria [14].
The misconceptions about causes of malaria such as
standing in the sun, eating oily foods held by the commu-
nity members in our study area are very similar to those
reported about 20 years ago in southern Ghana with sim-
ilar socio-cultural settings [15]. It is however encouraging
to note that majority of community members currently
associate malaria transmission with the mosquito. The
massive educational campaigns about malaria and its
control measures adopted as part of the Roll Back
Malaria strategies throughout Ghana may have contrib-
uted to this as evident by a significant increase in ITN use
in recent years in the study area; from 10% in 2003 to
about 60% in 2007, [10]. The majority of care-givers asso-
ciated high body temperature with malaria. This finding
is particularly important and suggests care-givers can
identify early symptom of malaria among children and
promptly seek care and appropriate therapy with ACTs if
available, accessible and affordable. The malaria treat-
ment practice of using left over antimalarials at home
identified among respondents could lead to sub-optimal
treatment of malaria and resistance to ACTs. Educational
campaigns need to be intensified and sustained in malaria
control programs.
Awareness of any health intervention greatly influences
an individual's health care-seeking behaviour. We recogn-
ise that since this study was conducted three to four years
ago some of the perceptions and behaviours reported
here might have changed over time. Nevertheless, major-
ity of respondents in this study were not aware of AS-AQ
as the new anti-malarial drug in place of chloroquine.
Awareness in the sampled population conducted in 2006
and the district wide surveys conducted in 2007 was
notably different. It is unclear why this differential in
awareness was found at these two time points but it may
be attributed to differences in knowledge of the respon-
dents in the surveys, a methodology limitation; the 2006
survey respondents targeted heads of households as com-
pared to the 2007 survey where any adult member of the
household was allowed to respond on behalf of the
household head.
Literacy among community members studied was low;
as such majority of participants were not able to mention
the name "artesunate-amodiaquine" correctly. This find-
ing is likely to be the same in most rural areas in sub-
Saharan Africa. A sustainable multi-prong, population
specific approach needs to be adopted especially in areas
where literacy is low if a maximum coverage of education
about AS-AQ is to be achieved. An acronym for AS-AQ
that is easily pronounced and recalled has to be intro-
duced so that it can be used as a household cliché. This
method of publicity has been used as educational tools in
health programmes such as the "he-ha-ho" communica-
tion campaign launched in Ghana to improve home-
based care of childhood diseases including malaria [16].
A pre-tested well-packaged message will generate discus-
sions among individuals in the community and propagate
information on AS-AQ.
A successful implementation of the change process
from monotherapy to ACTs depends on people's percep-
tion about the side-effects to a treatment drug. Popula-
tion perceptions have been known to adversely affect the
implementation of health programmes such as polio vac-
cinations in northern Nigeria [17] and de-worming pro-
gramme in Ghana [18]. In the year 2005, there was a
media outcry about the side-effects of AS-AQ in Ghana.
This led to the withdrawal of some brands of AS-AQ
from the market [19] and may have affected public confi-
dence, especially in the cities in Ghana. In the study area,
the main side-effects reported about AS-AQ by commu-
nity members include body weakness and dizziness. This
is similar to adverse event profile documented in con-
trolled trials of AS-AQ [20]. Effective educational mes-
sages about AS-AQ and its side-effects should be
maintained to ensure a positive perception about AS-AQ
in the community. The perception of health workers
about a drug could greatly influence its prescription pat-
terns. Health practitioners generally perceived AS-AQ as
a drug with some serious side-effects. Some practitioners
either refused to prescribe AS-AQ to their patients or
sometimes reduced the dosage of the drug for their cli-
ents as a way of preventing or minimising its side-effects.
This practice could lead to partial treatment and faster
growth of the parasite(s) resistance to ACT's. There is an
urgent need to continually monitor branded AS-AQ for
their quality due to earlier experience of having to with-
draw certain brands of AS-AQ from the Ghana market.
The affected manufacturers may find ways of re-intro-
ducing their rejected brands into the communities and
the reactions earlier experienced could be re-visited.
Availability of drugs and treatment options are crucial
for malaria control. One of the policies within the process
of change in Ghana was to dispense AS-AQ combination
through the government health facilities to ensure
accountability and correct usage. For instance, in rural
areas of Ghana, the drugs were dispensed in the govern-
ment rural clinics and not community chemical shops
which are the first point of call for malaria treatment in
the study areas. This could explain why the drugs were
available in the health institutions at the time of the sur-
vey and not in community chemical shops which are
accessible to community members and may have contrib-
uted to the low usage of AS-AQ allowing for the high use
of chloroquine and herbal preparations in our rural com-Asante et al. BMC Public Health 2010, 10:409
http://www.biomedcentral.com/1471-2458/10/409
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munities. The availability of AS-AQ and other ACTs in
the local chemical shops was found to be persistently low
as at January 2008 by USAID | DELIVER Project, Task
Order 3, and MSH/SPS Program which assessed antima-
larial drug supply chain in Ghana [21]. This pattern of
low usage of AS-AQ in the study area are similar to what
has been reported in other parts of Africa such as
Burundi [22] after AS-AQ implementation as first-line
drug for treating malaria.
Home management of malaria with ACTs including
AS-AQ has been found to be feasible in Ghana where AS-
AQ is now registered to be served over the counter with-
out a prescription [23-25]. Deployment of AS-AQ at the
community level through chemical shops and Commu-
nity Health Planning Service (CHPS) compounds would
therefore improve accessibility of the drug at the commu-
nity level. There is however the need to increase availabil-
ity of malaria diagnostic tools at the community level.
About 37.8% (95% CI 32.9%-42.7%) of all fevers reported
in a Mozambique national malaria survey were estimated
to be due to malaria [26]. The other febrile illnesses such
as respiratory tract infections of bacterial or viral origin
could contribute the higher proportion of all fevers. This
proportion of fever due to non-malaria diseases is likely
to increase over time given the current commitment to
malaria programmes that are targeting malaria elimina-
tion.
Rapid Diagnostic Tests (RDTs) for malaria using anti-
gen-based dipsticks have the potential to improve diag-
nosis of malaria and thereby reduce wastage of
antimalarial drugs [27]. A combination of RDT plus ACT
would improve not only the treatment of malaria but also
the clinical management of febrile illness in general; par-
ticularly pneumonia which is often misdiagnosed as
malaria in children [28] This would also reduce the
amount of antimalarial used and thus reduce the drug
pressure and selection of drug resistance. Studies are cur-
rently being conducted in Kintampo, Ghana to investi-
gate the benefit or otherwise of restricting ACT
treatment to diagnosed (RDT or microscopically)
malaria.
The high cost of AS-AQ in the private non-government
sector was a barrier to access. It is believed that this bar-
r i e r  w i l l  b e  m i n i m i z e d  w i t h  a n  i n c r e a s e  i n  N a t i o n a l
Health Insurance coverage in Ghana which is currently
about 38% [29]. Additionally existing and new funding
mechanisms such as the Affordable Medicines Facility -
m a l a r i a  ( A M F m )  h o s t e d  b y  t h e  G l o b a l  F u n d  t o  f i g h t
AIDS, Tuberculosis and Malaria seek to make ACTs
including AS-AQ affordable (about 0.05 USD) in the pri-
vate and public sectors [30]. However funding mecha-
nisms are usually time bound and its sustainability are
subject to various factors including availability of funds
and implementation performance. For instance the
AMFm facility is currently set up to run for a period of
only 24 months and may be renewed for the countries
currently involved or extended to other endemic coun-
tries in 2012 [30]. There is the need for endemic country
governments and their partners to guarantee the sustain-
a b i l i t y  o f  a f f o r d a b l e  A C T S  t o  e n s u r e  a v a i l a b i l i t y  a n d
accessibility in the private sector such as chemical shops
located within the communities.
The need to provide accessible alternatives to the group
of patients who react to AS-AQ is crucial as this would
prevent patients from treating themselves with mono-
therapies as an alternative treatment to AS-AQ. The
Ghana policy currently recognises artemether-lumefan-
trine as an alternative first-line malaria treatment drug so
that those who are unable to cope well with AS-AQ have
an alternative. While ensuring the availability of AS-AQ
at the community level, an effective pharmacovigilance
system needs to be in place to document rare adverse
events of AS-AQ. Additionally, an effective monitoring of
brands of AS-AQ on the market will be necessary to pre-
vent flooding of the market with unapproved AS-AQ
drugs.
Limitation
Participant understanding of the term 'malaria' could
vary among respondents. In this study focus group dis-
c u s s i o n s  w e r e  f i r s t  h e l d  w i t h  c o m m u n i t y  m e m b e r s  t o
assess the local names and descriptions of malaria. These
discussions helped to adequately establish local signs and
symptoms that describes the biomedical syndrome of
malaria. The local names and descriptions of malaria
were used to develop quantitative tools. This therefore
limited the possibility of participants misunderstanding
the term "malaria" for other illnesses. Pictures of common
antimalarial drugs were provided to respondents as aids
to elicit the type of antimalarial drugs used by community
members for their last malaria episode. Additionally,
observations of left over antimalarial packages were
made. This reduced the possibility of participant
response biases arising from the inability to pronounce
names of anti-malaria drugs used and time lapse (2
months) between time of last episode of malaria and time
of survey. Responses to treatment practices and aware-
ness of AS-AQ may have been influenced by recall biases.
Conclusion
In conclusion, the knowledge of fever as a symptom of
malaria is high among the study population. The aware-
ness of AS-AQ therapy and its side-effect is low in the
study area. Community education and sensitization tar-
geting all categories of the population has to be intensi-
fied to ensure an efficient implementation process. The
useful experiences and lessons learnt by Ghana in this
drug policy change process should be an experience thatAsante et al. BMC Public Health 2010, 10:409
http://www.biomedcentral.com/1471-2458/10/409
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could be utilised by other endemic countries that are in
the process of changing their anti-malarial drug policies.
We recognise this study was carried out just two years
after the policy change. Several experiences may unfold
over time and need to be documented carefully so as to
help steer the maximum compliance in the use of the AS-
AQ and other ACTs in endemic countries.
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